Contrasting PD1 blockade responses and immunogenomic contexts in MSI high rectosigmoid adenocarcinomas
This paper reports two cases of MSI-H rectosigmoid adenocarcinoma with divergent responses to tislelizumab monotherapy, illustrating that beyond standard biomarkers like TMB and PD-L1, specific genomic alterations such as HLA class I loss of heterozygosity, WNT-pathway dysregulation, and SMARCA4 mutations may critically influence treatment resistance.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
In the fight against colorectal cancer, doctors have long relied on a specific biological signature to decide who might benefit from a powerful new class of drugs called immune checkpoint inhibitors. These drugs work by removing the brakes on the body's own immune system, allowing it to recognize and destroy cancer cells. For a subset of patients whose tumors carry a defect in their DNA repair machinery, known as mismatch-repair deficiency, these drugs have been nothing short of revolutionary. In many cases, the treatment shrinks tumors so completely that surgery is no longer needed, offering a chance at a cure without the physical toll of a major operation. However, the medical community has faced a persistent puzzle: not every patient with this specific genetic defect responds to the treatment. Some see their cancer vanish, while others see it stabilize briefly before growing again. Understanding why this happens is critical, as it determines whether a patient receives a life-saving therapy or is left waiting for a different solution.
A recent report from a hospital in Beijing offers a rare, side-by-side look at this mystery. The researchers followed two men who were treated at the same time, in the same place, for nearly identical, advanced tumors in the lower part of their colon. Both men had the same genetic signature that usually predicts a strong response to immunotherapy. Both received the same drug, tislelizumab, as their primary treatment. Yet, their journeys ended in completely different ways. One man achieved a complete and lasting disappearance of his cancer, while the other saw his disease return and progress despite months of therapy. By comparing the detailed genetic maps of their tumors, the authors found that the difference lay not in the broad genetic category they shared, but in specific, hidden features of their cancer's internal architecture that either invited the immune system in or kept it out.
The first patient was a fifty-eight-year-old man with a long history of a chronic inflammatory bowel condition. His tumor was large and had spread to nearby tissues, but when doctors examined its genetic code, they found it was teeming with mutations—nearly seventy-seven changes per million DNA letters. This high number of errors usually signals a tumor that is easy for the immune system to spot. When the drug was administered, the tumor began to shrink rapidly. After nearly a year of treatment, scans showed no sign of the cancer. The patient was placed on a "watch and wait" plan, and when surgery was eventually performed to address his underlying bowel condition, the removed tissue showed no trace of the original tumor. The cancer had been eradicated completely.
The second patient was a thirty-three-year-old man with a family history of a hereditary cancer syndrome. His tumor was also large and aggressive, and it too carried the same genetic signature of DNA repair failure. His tumor also had a high number of mutations, though slightly fewer than the first patient's. He received the exact same drug. Initially, the treatment seemed to work; the tumor stopped growing, and his blood markers improved. But within a year, the cancer began to grow again. Despite switching to different combinations of drugs, the disease continued to advance, eventually requiring a massive surgery to remove the tumor and surrounding organs.
The key to understanding this divergence was found in the fine print of their genetic reports. While both tumors shared the main "green light" for immunotherapy, the second patient's tumor carried a set of additional genetic alterations that acted like a shield. His cancer had lost the ability to display its identity to the immune system, a process controlled by specific genes that were broken or missing. Furthermore, his tumor had mutations that are known to create a hostile environment for immune cells, effectively hiding the cancer from attack. In contrast, the first patient's tumor, while also carrying some genetic damage, lacked these specific shielding mechanisms. Instead, his tumor had different genetic changes that, paradoxically, may have made it even more visible to the immune system.
The researchers also noted that the first patient's long-standing bowel inflammation did not prevent the treatment from working, nor did it cause a dangerous flare-up of his condition during the therapy. This is a significant observation, as doctors often worry that stimulating the immune system in patients with chronic inflammation could trigger severe complications. The fact that this patient tolerated the treatment well suggests that such individuals should not be automatically excluded from these life-saving therapies.
This case study does not prove that these specific genetic markers are the sole reason for the different outcomes, as the sample size is very small. However, it strongly suggests that looking only at the broad category of DNA repair defects is not enough. To predict who will truly benefit from immunotherapy, doctors may need to look deeper, checking for these specific "shielding" genes and other hidden genetic features. The story of these two men illustrates that even when two patients appear to have the same disease and receive the same treatment, the microscopic details of their cancer's genome can dictate a completely different fate. It highlights the urgent need for more detailed genetic testing to guide treatment decisions, ensuring that the right patients receive the right therapy at the right time.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.